Allergic rhinitis, allergic contact dermatitis and disease comorbidity belong to separate entities with distinct composition of T-cell subsets, cytokines, immunoglobulins and autoantibodies

Wenjia Chai1,2†, Xuyi Zhang3†, Meixiong Lin3, Zhuo Chen3, Xiaolin Wang1,2, Changqing Wang4, Aoyan Chen4, Caisheng Wang4, Hongwu Wang4*, Honghong Yue3,4* and Jingang Gui1,2*

Abstract

Background: Allergic rhinitis (AR) and allergic contact dermatitis (ACD) are prevalent allergic diseases and have significant impacts on patients’ daily life. Despite many studies on AR or ACD have been conducted separately, little is known about the immune responses in patients of AR combined with ACD and the interplay between AR and ACD. Our study compared various aspects of immune elements in patients with AR or/and ACD, aiming to characterize the immune responses in AR, ACD, and AR combined with ACD.

Methods: A total of 57 patients diagnosed with AR or/and ACD and 28 healthy volunteers were included. AR patients were further divided into seasonal AR (SAR) and perennial AR (PAR). All subjects’ blood samples were taken to assess the concentration of immunoglobulins, complement C3, C4, autoantibodies and cytokines in serum by immunoturbidimetry, ELISA or Luminex200 platform. Peripheral blood mononuclear cells (PBMCs) were subjected to the analysis of lymphocyte subpopulations by flow cytometry.

Results: It indicated that AR disease caused elevated levels of IgE, IgA, IgG, IgG4, as well as IL-4, IL-15, IL-8 and IL-6 in serum. AR patients possessed a decreased CD4/CD8 ratio and an increased proportion of memory CD4 T-cell subset, with a skewed Th2 response and an enhanced CD8+ T-cell activation. Compared with patients with sole AR or ACD condition, AR+ACD patients presented with a significantly increased proportion of memory CD8+ T-cell subset and were prone to autoimmune disorders as indicated by the increased autoantibodies. The immune elements...
Background

Allergic rhinitis (AR) and allergic contact dermatitis (ACD) are common allergic diseases worldwide characteristic of high IgE and allergic inflammation readily triggered by allergens [1, 2]. AR is the most prevalent mucosal inflammation condition generally manifested with sneezing, nasal congestion, nasal itching and rhinorrhea [1]. It is believed that AR is closely related to the inhaled allergen, while ACD is directly connected with skin exposure [2]. Clinical presentations of ACD in acute phase include pruritus, dryness, erythema and scaling. It can develop into chronic inflammatory conditions upon continuous allergen exposure, and the exact mechanism remains unknown [3, 4]. The diagnoses of AR and ACD mainly depend on the occurrence history, regular clinical laboratory tests, skin prick tests and epicutaneous patch tests [2, 5]. Avoidance of allergens is one of the crucial measures for restraining atopic conditions of AR and ACD. While traditional drugs such as antihistamines and corticosteroids can relieve the symptoms, there is no known cure with only the allergen-specific immunotherapy (AIT) lighting a hope for complete remission [1, 2]. Further studies demonstrated that in nasal secretions, various cytokines including IL-4, IL-1, IL-2, IL-6, GM-CSF and TNF-α were implicated in AR development and progress [13, 14]. In addition, Treg cells, characterized by the production of anti-inflammatory cytokines such as IL-10 and TGF-β, are likely to be important in the control and resolution of AR [15–17]. There is a growing appreciation that AR is not only a disease restricted to nasal passages, but also a manifestation of systemic airway disease [6]. It will be meaningful to investigate the immune process in peripheral blood in addition to nasal secretions.

By contrast, ACD is a delayed type IV hypersensitivity reaction resulting from the activation of allergen-specific T cells [18]. ACD occurs in the dermis and epidermis, where specific T cells are activated by hapten and an inflammatory cascade is triggered [18]. In light of the knowledge from studies on AR and ACD, it has been accepted that they share similarities of many aspects in their pathogenesis and immune responses. For instance, their allergic inflammatory presentations are driven by multiple immune pathways, especially T-cell mediated immunity [19, 20]. Nevertheless, it remains elusive whether AR would march faster or become worse from the immunological perspective when ACD is accompanied, or vice versa. In other words, it is not known yet if these two conditions would interplay and reshape the immune response reciprocally, or they merely belong to two independent entities. Through dissecting various immune features of patients with AR/ACD only or AR concomitant with ACD, our study aims to find the clue to the relationship, if any, between these two highly frequent atopic conditions.

Methods

Patients

The present study recruited 57 patients diagnosed with AR and/or ACD and 28 healthy volunteers aged from 19 to 35 years. The information of the patients and healthy
controls was displayed in Table 1. All subjects, including healthy volunteers, were subjected to skin prick tests and epicutaneous patch tests. Diagnosis of AR was based on medical history, clinical laboratory findings and skin prick tests according to ARIA guidelines [5]. Based on the results from skin prick tests on cyclic pollens or year-round allergens (summarized in Table 2), AR patients were divided into SAR or PAR. Diagnosis of ACD was made according to medical history, physical examination and confirmed by the epicutaneous patch tests. AR combined with ACD patients were defined as the AR+ACD group. The study was approved by the Medical Ethics Committee of Third Medical Center of Chinese PLA General Hospital and Inner Mongolia Xilinguo League Central Hospital. Written consents were provided by all participants.

Skin prick test and epicutaneous patch tests
Skin prick tests were performed for the common inhalant allergens in China, including dust mite (Dermatophagoides pteronyssionus, Dermatophagoides farinae), trees pollen (Common silver birch, Mountain juniper), and weeds pollen (Mugwort, Japanese Hop). All extracts were prepared from the Allergen Manufacturing and Research Center (Peking Union Medical College Hospital, Beijing, China). Histamine phosphate (0.01 mg/ml) was used as the positive control, and an allergen diluent (normal saline solution) as the negative control. The results were evaluated 15 min after application. A wheal diameter ≥ 5 mm after subtracting the negative control for each of the allergens tested was considered as a positive response. The results were listed in Table 2.

The epicutaneous patch (manufactured by Rainmix Biotechnology, Anhui, China) tests were performed on the upper back and evaluated after 48 and 72 h. The test reactions were graded from no reaction to grade +, ++, and +++, depending on the intensity of the reaction following the recommendations of the International Contact Dermatitis Research Group [21]. The results were listed in Table 3.

Flow cytometry
For surface marker labeling, 50 μl EDTA anticoagulated blood of each sample was incubated with fluorochrome-conjugated antibodies for 20 min in dark. After that, 450 μl OptiLyse C (Beckman Coulter, USA) was added for erythrocytes lysis. Following 10 min incubation in dark, 50 μl absolute count beads (Biolegend, USA) were added before events of stained cells were acquired with a FACS CantoII flow cytometer (BD Biosciences, USA).

For intracellular labeling, PBMCs were isolated with Ficoll-Hypaque density gradients. After centrifuging at 1000g for 20 min at room temperature, the interphase cell layer was carefully transferred into a 15 ml tube. The cell pellet was washed with 10 ml PBS containing 5% FBS and centrifuged at 600g for 5 min. For cytokine detection, 2 × 10^6 cells of each sample were cultured in 10% FBS RPMI-1640 medium (Gibco, USA) with 50 ng/ml of PAM (Sigma, USA), 1 μg/ml Ionomycin (Yeastem, China) in the presence of 1 μg/ml Brefeldin A (Yeastem, China) at 37 °C cell incubator with 5% CO2. Then cells were permeabilized using Fixation/Permeabilization Solution Kit (BD Biosciences, USA) according to the manufacturer’s protocol after surface marker labeling. Cell events were acquired with FACS CantoII flow cytometer (BD Biosciences, USA) and data were analyzed with FlowJo (v10, Tree Star). Following antibodies were used: For surface marker labeling: CD3 APC-H7, CD4 BV421, CD8 APC-R700, CD19 PE-Cy7, CD16 V500, CD56 PerCP-Cy5.5, CD45RA APC, CD45RO FITC. For

### Table 1 Patient information

| Group         | Gender (female/male, n) | Age (years ± SEM) |
|---------------|-------------------------|-------------------|
| HC (n=28)     | 12/16                   | 25.57±1.01        |
| AR (n=30)     | 12/18                   | 27.93±0.8         |
| ACD (n=12)    | 6/6                     | 24.17±1.19        |
| AR+ACD (n=15) | 6/9                     | 26.53±1.32        |

### Table 2 Results of skin prick tests

| Allergen       | Positive (n, %) |
|----------------|----------------|
|                | HC (n = 28)    | AR (n = 30)    | AR+ACD (n = 15) | ACD (n = 12) |
| Mite           |                |                |                |
| D. pteronyssionus | 0              | 11, 36.7%      | 7, 50%          | 0            |
| D. farinae     | 0              | 11, 36.7%      | 7, 50%          | 0            |
| Trees pollen   |                |                |                |
| Common silver birch | 0            | 4, 13.3%       | 2, 13.3%        | 0            |
| Mountain juniper | 0              | 18, 50%        | 7, 50%          | 0            |
| Weeds pollen   |                |                |                |
| Mugwort        | 0              | 2, 6.7%        | 3, 20%          | 0            |
| Japanese Hop   | 0              | 5, 16.7%       | 4, 26.7%        | 0            |
intracellular labeling: CD4 PerCP-Cy5.5, CD8 PE-Cy7, IL-4 PE, IFN-γ APC, granzyme B FITC. All antibodies were purchased from BioLegend.

Measurement of serum cytokines
According to the manufacturer's instructions of the Human Cytokine/Chemokine Panel MILLIPLEX® MAP kits (Cat. No. HCYTOMAG-60K: IFN-γ, IFN-α2, IL-1β, IL-1α, IL-8, IL-4, IL-10, IL-12(p70), IL-15, IL-17A, TNF-α) (Merck Millipore, Germany), serum concentrations of multiple cytokines were measured by a Luminex200 platform (Merck Millipore, Germany). In brief, the plate was pretreated with 200 μl wash buffer for 10 min. Next, 25 μl serum of each sample, 25 μl assay buffer and 25 μl mixed beads were added to sample wells. The background wells, QC wells and standard wells were added with corresponding reagents following the instructions. The plate was sealed and incubated with shaking at 4 °C overnight. The next day, the plate was washed twice with wash buffer and 25 μl detection antibodies were added for a 1 h incubation at room temperature. After washed twice with wash buffer, each well was incubated with 25 μl Streptavidin Phycoerythrin for 30 min. After two wash steps, 150 μl sheath fluid was added and the data were collected by the Luminex200 platform. All samples were measured in duplicate.

Measurement of serum immunoglobulin, IgG4, C3, C4 and autoantibodies
Serum IgG, IgA, IgM and C3, C4 were measured by immunoturbidimetry using an automated Beckman Image 800 Immunochemistry System (Beckman Coulter, USA) according to the manufacturer's instructions. Serum IgE was measured by ELISA using EUROIMMUN Analyzer I (Euroimmun, Germany) according to the manufacturer's instructions. Serum IgG4 was measured by ELISA (SAB, USA). Serum autoantibodies (nRNP, Sm, SS-A, Ro-52, SS-B, Scl-70, PM-Scl, Jo-1, CENP B, PCNA, dsDNA, NUCL, Histones, rib-P, AMA-M2) were measured by EUROBlotMater and the data were analyzed by EUROBlotCamera (Euroimmun, Germany).

Table 3 Results of epicutaneous patch tests

| Allergena | Positive (n, %) | HC (n = 28) | AR (n = 30) | ACD (n = 12) | AR + ACD (n = 15) |
|-----------|----------------|------------|------------|-------------|------------------|
| Potassium dichromate | 0 | 0 | 3, 25% | 2, 13.3% |
| Ursol | 0 | 0 | 5, 41.7% | 5, 33.3% |
| Paraben mix | 0 | 0 | 3, 25% | 0 |
| Cobalt chloride | 0 | 0 | 3, 25% | 1, 6.7% |
| Nickel sulfate | 0 | 0 | 1, 8.3% | 4, 26.7% |
| Colophony | 0 | 0 | 1, 8.3% | 1, 6.7% |
| Fragrance mix | 0 | 0 | 0 | 2, 13.3% |
| Thiomersalate | 0 | 0 | 0 | 2, 13.3% |
| Quaternium-15 | 0 | 0 | 0 | 3, 20% |
| P-tert-butyl phenol formaldehyde resin | 0 | 0 | 0 | 1, 6.7% |

* Kathon CG, formaldehyde, bronopol, quadrol, mercaptobenzothiazole, carba mix, rubber mix, N-cyclohexylthiopeptide lipid, quinol and epoxy resin are not listed in the table on account of none of the subjects showed positive reaction for these allergens.

Results
Differential levels of serum immunoglobulins and cytokines in AR or/and ACD patients
A total of 57 patients diagnosed with AR or/ and ACD aged from 19 to 35 years were included in the study. AR combined with ACD patients were defined as the AR + ACD group. Results for skin prick tests and epicutaneous patch tests were listed in Tables 2 and 3. As expected, all healthy volunteers showed no reaction in response to these allergens.

We firstly investigated the serum levels of immunoglobulin and complement C3, C4. IgE played a key role in type I hypersensitivity mediating various atopic diseases [22]. Indeed, the results showed levels of IgE were elevated in all three patient groups (Fig. 1A). Interestingly, compared with those in HCs, IgA, IgG and IgG4, one of the subclasses of IgG, were elevated in
AR group and AR+ACD group, but not in ACD group (Fig. 1B–D). It implied that the IgG and IgA levels were disturbed in AR patients but not in patients afflicted with ACD only. By contrast, the serum IgM and complement C3, C4 were all at comparable levels to controls (Additional file 1: Fig S1A–C).

Next, we examined the levels of serum cytokines (IFN-γ, IFN-α2, IL-1β, IL-1α, IL-8, IL-4, IL-6, IL-10, IL-12(p70), IL-15, IL-17A, TNF-α) in each group by Luminex200 platform. Our data revealed that serum IL-6 remarkably increased in both AR group and AR+ACD group, compared to that in HCs (Fig. 1E). Surprisingly, IL-4, IL-15 and IL-8, three important pro-inflammatory cytokines that involved in Th2 response were found elevated in patients with AR only (Fig. 1F–H), but not in AR+ACD group and ACD group (Fig. 1F–H). Other cytokines were not found to have any difference among different groups (Additional file 1: Fig S1C–J).

**Lymphocytes subsets in the peripheral blood of patients with AR or/and ACD**

In parallel, the lymphocytes subsets in peripheral blood from indicated groups were investigated. Representative FACS plots of the HC group and gating strategy were shown (Fig. 2A). Compared with HC group, the percentage of lymphocytes was decreased in AR group (Fig. 2B). While CD4+CD3+T cells did not show a significant change, an increase in CD8+CD3+T cells was observed in AR group, but not in ACD group or AR+ACD group (Fig. 2C, D). As a result, CD4/CD8 ratio was decreased in AR group (Fig. 2E). There was no significant difference observed in CD19+B cells and CD3-CD56+CD16+NK cells among four groups (Additional file 1: Fig S2A, B).

Considering that memory T cells have been observed playing a role in allergic responses [23], we examined the proportion of memory/naive T cell subsets in different patient groups and HCs. An increased proportion of CD45RO+CD45RA-memory CD4+T cells were observed in AR group (Fig. 2F). Whereas, AR+ACD group presented with an elevated proportion of CD45RO+CD45RA-memory CD8+T cells (Fig. 2G). The immune cell compartments in patients with ACD only were minimally disturbed. Neither memory CD4 nor memory CD8+T cells had any ratio change in ACD patients compared to HCs (Fig. 2F, G).

In sum, AR patients showed the most intense impact on the immune components reflected by an elevation of various serum cytokines (IL-4, IL-15, IL-8, IL-6) as well as a reduced CD4/8 ratio in addition to an augmented memory CD4+T-cell compartment in the peripheral circulation. AR+ACD group was featured with a moderate change in serum cytokines (increased in IL6 expression only) and an increased ratio in peripheral memory CD8+T cells. Based on our data, it was perceivable that cytokines and T-cell compartment in patients with ACD only were least affected in comparison with other allergic conditions.
Decreased IFN-γ + CD4+ /IL-4 + CD4+ cells and increased granzyme B + CD8+ T cells in AR patients

To dissect the T-cell function in these patient groups, intracellular staining for Th1-related cytokine (IFN-γ), Th2-related cytokine (IL-4) and lytic granule (granzyme B) in T-cell subsets were performed. A reduction of IFN-γ + CD4+ subset was observed in AR group (Fig. 3A). Although there was no significant change in the IL-4 + CD4+ subset, the ratio of IFN-γ + CD4+ (Th1)/IL-4 + CD4+ (Th2) showed a decrease in AR group (Fig. 3B, C). Moreover, the proportion of granzyme B + CD8+ T cells was increased while IFN-γ + CD8+ T cells showed no change (Fig. 3D, E). It indicated the imbalance of Th1/Th2 and the activation of CD8+ T cells in AR group.

Higher incidence and broader spectrum of autoantibodies in AR + ACD patients

Previous research has established that autoantibodies were involved in the pathogenesis of autoimmune
diseases [24]. To investigate if the long-term allergic conditions could trigger autoimmunity leading to the production of autoantibodies, we characterized the profile of autoantibodies (IgG) (nRNP, Sm, SS-A, Ro-52, SS-B, Scl-70, PM-Scl, Jo-1, CENP B, PCNA, dsDNA, NUCL, Histones, rib-P, AMA-M2) in the serum of patients. We defined “autoantibody (IgG) positive rate” as the percentage of positive individuals in each group. When a patient showed one or more autoantibody reactivity in the autoantibody profile test, he or she was defined as an autoantibody-positive individual.

The results showed that the autoantibody positive rate in AR and ACD groups was 26.7% and 25%, respectively (Fig. 4A). Strikingly, in the AR + ACD group, the positive rate was increased to 53.3%, which implied the additive effect of AR and ACD towards autoimmunity (Fig. 4A). As shown in Fig. 4B illustrating the profile of autoantibodies presentation, several patients showed multiple autoantibody specificities. It appeared that the histones IgG was the prevalent autoantibodies in AR patients (Fig. 4B). Moreover, AR + ACD group presented with a more diversified autoantibody spectrum (Fig. 4B).

In other words, AR group had a histones autoantibody bias, and AR + ACD group possessed a higher positive rate and a broader spectrum of autoantibodies. Taking together, these results suggested an association of autoimmune propensity with these allergic diseases to various extents.

**Different immunoglobulin levels, cytokines expression and T-cell subsets between PAR and SAR patients**

Considering AR group exhibited significant differences in several cytokines and T-cell subsets compared with HC group, a more detailed analysis was made. AR patients were divided into SAR (n = 27) or PAR (n = 16) depending on the reactivity of skin prick tests to cyclic pollens or year-round allergens (mite) (Table 2). Two patients exhibiting positive reactions to both cyclic pollens and mite were excluded. Data segregation for AR patients revealed that total serum IgA and IgE levels were elevated in both SAR and PAR patients, while total IgG level was only increased in SAR patients (Fig. 5A–C). Cytokine analysis showed an increase of IL-4 and IL-15 in the SAR patients, while IL-6 and IL-8 were
Fig. 4 AR+ACD patients showed higher positive rate and broader spectrum in autoantibody (IgG) profile. A The percentage of patients with positive reactions to autoantibodies in each group was shown. When a patient showed one or more autoantibody reactivity in the autoantibody profile test, he or she was defined as an autoantibody-positive individual. B Autoantibody profile of each patient group was shown. The percentage was calculated as the numbers of seropositivity for each autoantibody compared to the total number of positive reactions of each group.

Fig. 5 PAR and SAR patients serum exhibited different cytokine profiles. A-C The serum levels of IgE were measured by ELISA, IgA and IgG were measured by immunoturbidimetry. D-G The concentration of IL-4, IL-15, IL-8 and IL-6 were determined by the Luminex200 platform. HC, healthy controls, n = 28; PAR, perennial allergic rhinitis, n = 16; SAR, seasonal allergic rhinitis, n = 27. *p < 0.05, **p < 0.01, and ***p < 0.001 (one-way ANOVA and Tukey’s multiple comparisons test).
Chai et al. Allergy, Asthma & Clinical Immunology (2022) 18:10

in patients with ACD might be a sequela from a vicious circle of sensitization to other allergens due to repeated skin barrier disruption [27]. During the late phase of allergic process, IgE is released and binds to high-affinity receptor FceRI on the surface of mast cells and basophils [10, 26]. Following allergens binding to allergen-specific IgE, a complex cascade of mediators releasing is triggered [10, 26]. By contrast, allergen-specific IgG, which is also induced by allergen, can downregulate IgE-mediated anaphylaxis by masking allergens and crosslinking with FceRI and FcyRIIb [28, 29]. On the other hand, IgG could induce an allergic process by activating FcγRs on different cell types when allergen levels are high [30]. The elevation of serum IgG was also found in the mouse model of AR disease [31], besides, the nasal IgG was higher in AR patients compared with healthy controls [32]. There are four subclasses of IgG (IgG1, IgG2, IgG3 and IgG4). The inhaled allergens were strongly associated with serum IgG4 response [33]. Production of IgG4 in allergen-specific immunotherapy (AIT) is an immunological hallmark for successful tolerance establishment [34]. During AIT, AR patients showed a higher increase in serum IgG4 compared to patients with asthma symptoms [35]. Similarly, previous studies found a higher IgG4 level in nasal secretion and serum of AR patients [36, 37]. The fact that IgG4, an immunosuppressive mediator, increased in AR and AR+ACD patients implied that a complex negotiation between allergic inflammation and
tolerance was established in these patients. IgA mainly occurs as a monomer form in serum, and it is found as secretory IgA in secretion [38]. It has been reported that the salivary and nasal but not serum IgA levels were increased in AR patients [39, 40]. Deficiency in IgA may cause a change in the mucosal defense preceding the onset of allergy [41]. Other studies reported that a high level of IgA may be associated with mitigation of allergic symptoms, while other data indicated that allergen-specific IgA induced eosinophil degranulation [42–44].

The role of IgA in allergic disorders remains unclear. Our results found remarkably increased IgG and IgA levels in AR and AR + ACD patients, but not in the ACD patients. Based on our multiple measurements on immunological elements, we boldly believe that AR has a much intensive impact on systemic immunity while ACD’s influence is more locally constrained.

In cytokines/chemokines determination, AR patients expressed elevated levels of IL-4, IL-15, IL-8 and IL-6, while AR + ACD patients only showed an increase in IL-6. However, patients with ACD did not show any significant change in these cytokines. IL-4 is a characteristic Th2 cytokine critical for IgE-mediated inflammatory response [45]. IL-6 is a typical pro-inflammatory cytokine [11, 12]. IL-8 is a chemotactic cytokine for neutrophils and primed eosinophils [46]. IL-15 has been reported to be induced by allergen-specific Th2 cells [47]. It plays important roles in T cell activation and homeostasis, survival of B cells, mast cells and eosinophils [48, 49]. Meanwhile, it has been documented that in the nasal lavage fluid of AR patients, the expression of IL-4 and IL-6 increased [50, 51]. Additionally, there is evidence showing that IL-15 prevents AR through the reactivation of antigen-specific CD8+ cells [52]. Likewise, in a context of a more intensive impact on system immunity in AR versus the other two allergic conditions, multiple cytokine changes were found only in AR patients. ACD or comorbidity of AR and ACD seemed a different disease entity from AR based on the cytokine expression profile. Increased IL-6 in AR + ACD patients is possibly an intermediate responder along with the allergy march from ACD to ACD + AR. This conjecture was consolidated by the fact that increased IL-6 in AR mainly occurred in PAR patients, a condition with milder inflammation than SAR [53, 54]. Why PAR patients are the major contributors to IL-8 elevation in the AR group is hard to explain. Our impression is that PAR patients retained a chronic inflammation rather than an acute response in SAR due to their long-term allergen exposure.

The presence of autoantibodies in serum reflects leakiness of central and/or peripheral tolerance and may lead to the manifestation of autoimmune diseases [24]. A plethora of evidence has suggested that serum autoantibodies participate in the progress of allergic diseases [55, 56]. We confirmed that a higher incidence of AR patients presented with autoantibodies in blood samples, with histones as the prevalent antigen, which is congruent with previous studies in animal models [55]. Worth to mention, AR + ACD patients showed higher incidence and more diversified autoantibodies than patients with sole AR or sole ACD. It suggested that comorbidity of AR and ACD poses the patient higher risk for autoimmune disorders.

In lymphocytes subsets analysis, a significant decrease of CD4+/CD8+ ratio in AR patients was observed. Several previous studies showed no significant difference in CD4+ T cells in AR patients, but some others found increased CD4+ T cells [57–59]. It might own to different allergens or the severity of the disease. Allergic inflammation is mainly driven by Th2 cells [9]. IL-4 is a typical Th2-cytokine, and IFN-γ can be produced by Th1 cells [60]. We found a decrease in IFN-γ + CD4+ /IL-4+ CD4+ ratio in AR patients, which indicated the imbalance of Th1/Th2 in AR. Besides, AR patients showed an increase in memory CD4+ T cells and a decrease in naïve CD4+ T cells, while AR + ACD patients showed similar changes in CD8+ T cell subsets. The allergic condition lead to the formation of a pool of memory allergen [19], while AR and AR + ACD had different preferences in the induction of CD4+ and CD8+ T cells. Moreover, SAR patients exhibited significant changes in memory/naïve subsets of both CD4+ and CD8+ T cells while this was not true for PAR patients. It might be a result from a more pronounced allergenicity in cyclic pollens SAR patients encountered.

Conclusions
In conclusion, our study characterized the immune responses in AR, ACD and AR combined with ACD. AR patients showed elevated serum levels of IgE, IgA, IgG, IgG4, as well as IL-4, IL-15, IL-8 and IL-6. Furthermore, IL-4 and IL-6 were elevated in SAR patients, while IL-6 and IL-8 were elevated in PAR patients, which hinted the different tendencies of immune responses. What’s more, AR disease caused a decreased CD4/CD8 ratio and an imbalance in T cell subsets, including the increased proportion of memory CD4+ T cells, skewed Th2 response, and enhanced CD 8+ T cells activation. SAR but not PAR caused intense changes in T cell subsets. Despite not intensifying the immune responses, comorbidity of AR with ACD presented with an increased proportion of memory CD8+ T cells and an increased propensity for autoimmune disorders.
Abbreviations
AR: Allergic rhinitis; ACD: Allergic contact dermatitis; Ig: Immunoglobulin; PBMC: Peripheral blood mononuclear cells; IL: Interleukin; IFN-γ: Interferon-γ; ANOVA test: Analysis of variance test.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13223-022-00646-6.

Acknowledgements
The authors thank the patients and volunteers for their participation in this study.

Author’s contributions
WC performed experiments, analyzed data, and wrote the manuscript; XZ, ML, ZC and KW performed experiments and analyzed data; CW, AC and CW participated in the experiments; HW, HY and JG designed, conceived, and supervised the study and wrote the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by grants from a startup research fund to JG from Beijing Children’s Hospital, a teaching hospital affiliated to Capital Medical University, Clinical Research Supporting Fund of the Third Medical Center of Chinese PLA General Hospital (wz2017007) and Beijing Natural Science Foundation Program (7204259).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
The study was conducted with approval from the Medical Ethics Committee of Third Medical Center of Chinese PLA General Hospital and Inner Mongolia Xilinguo League Central Hospital. Informed consent was obtained from all subjects in accordance with the Declaration of Helsinki, and each subject provided written informed consent.

Consent for publication
All patients’ parents/guardians provided written informed consent for the publication of information resulting from the results without any personally identifying information.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Laboratory of Tumor Immunology, Beijing Pediatric Research Institute, Beijing 100000, China. 2 Department of Allergy, Inner Mongolia Xilinguo League Central Hospital, Xilinhot 026000, China.

Received: 8 September 2021 Accepted: 6 January 2022 Published online: 11 February 2022

References
1. Bousquet J, Anto JM, Bachert C, Biaiardi I, Boscin-Anticevich S, Walter CG, et al. Allergic rhinitis. Nat Rev Dis Primers. 2020;6(1):95.
2. Nasu S, Fonacier L. Allergic contact dermatitis. Med Clin North Am. 2020;104(1):61–76.
3. Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF. Allergic and irritant contact dermatitis. Eur J Dermatol. 2009;19(4):325–32.
4. Rashid RS, Shim TN. Contact dermatitis. BMJ. 2016;353:i2299.
5. Brozek JL, Bousquet J, Agache I, Agarwal A, Bachert C, Boscin-Anticevich S, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines—2016 revision. J Allergy Clin Immunol. 2017;140(4):950–8.
6. Kakih HA, Riley TD. Allergic rhinitis. Prim Care. 2016;43(3):465–75.
7. Ozdoganoglu T, Songu M. The burden of allergic rhinitis and asthma. Ther Adv Respir Dis. 2012;6(1):11–23.
8. Greiner AN, Hellings PW, Rotrof G, Scadding GK. Allergic rhinitis. Lancet. 2011;378(9809):2112–22.
9. Bernstein DI, Schwartz G, Bernstein JA. Allergic rhinitis: mechanisms and treatment. Immunol Allergy Clin North Am. 2016;36(2):261–78.
10. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693–704.
11. Geha RS, Jabara HH, Brodeur SR. The regulation of immunoglobulin E class-switch recombination. Nat Rev Immunol. 2003;3(9):721–32.
12. Gauchat JF, Henchoz S, Mazeggi G, Aubry JP, Brunner T, Blasey H, et al. Induction of human IgE synthesis in B cells by mast cells and basophils. Nature. 1993;365(6444):340–3.
13. Fireman P. Cytokines and allergic rhinitis. Allergy Asthma Proc. 1996;17(4):175–8.
14. Verschoor D, von Gunten S. Allergy and atopic diseases: an update on experimental evidence. Int Arch Allergy Immunol. 2019;180(4):235–43.
15. Bottun K, Lacerde Y, Cavaillas A, Versolet D, Magnan A. Differences in allergen-induced T cell activation between allergic asthma and rhinitis: role of CD28, ICOS and CTLA-4. Respir Res. 2011;12:25.
16. Van Overtvelt L, Wambre E, Mailiere B, von Hufe E, Louise A, Balazuc AM, et al. Assessment of Bet v 1-specific CD4+ T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramers. J Immunol. 2008;180(7):4514–22.
17. Zhang LX, Liu T. Treg influences the pathogenesis of allergic rhinitis through TICAM-1 pathway. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2018;32(22):1763–6.
18. Imbesi S, Minciullo PL, Isola S, Gangemi S. Allergic contact dermatitis: immune system involvement and distinctive clinical cases. Allergol Immunopathol (Madr). 2011;39(6):374–7.
19. Woodfolk JA. T-cell responses to allergens. J Allergy Clin Immunol. 2007;119(2):280–94 (quiz 95–6).
20. Sustiel A, Rocklin R T cell responses in allergic rhinitis, asthma and atopic dermatitis. Clin Exp Allergy. 1989;19(1):11–8.
21. Pongpaipoj K, Ale I, Andersen KE, Bruze M, Diepgen TL, Elsner PU, et al. Proposed ICDRG classification of the clinical presentation of contact allergy. Dermatitis. 2016;27(5):249–58.
22. De Schryver E, Devuyst L, Derycke L, Dullaers M, Van Zele T, Bachert C, et al. Local immunoglobulin E in the nasal mucosa: clinical implications. Allergy Asthma Immunol. 2015;7(4):321–31.
23. Woodfolk JA. T-cell responses to allergens. J Allergy Clin Immunol. 2007;119(2):280–94.
24. Ludwig RJ, Yanhouorebeke K, Leypoldt F, Kaya Z, Bieber K, McLachlan SM, et al. Mechanisms of autoantibody-induced pathology. Front Immunol. 2017;8:603.
25. Zellweger F, Eggel A. IgE-associated allergic disorders: recent advances in etiology, diagnosis, and treatment. Allergy. 2016;71(12):1652–61.
26. Finkelman FD, Khodoun MV, Strat R. Human IgE-independent systemic anaphylaxis. J Allergy Clin Immunol. 2016;137(6):1674–80.
27. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203):445–54.
28. Zhu D, Kepley CL, Zhang M, Zhang K, Saxon A. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat Med. 2002;8(5):518–21.
29. Burton OT, Logsdon SL, Zhou JS, Medina-Tamayo J, Abdel-Gadir A, Noval RM, et al. Oral immunotherapy induces IgG antibodies that act through AR: Allergic rhinitis; ACD: Allergic contact dermatitis; Ig: Immunoglobulin; PBMC: Peripheral blood mononuclear cells; IL: Interleukin; IFN-γ: Interferon-γ.
FcgammaRIIb to suppress IgE-mediated hypersensitivity. J Allergy Clin Immunol. 2014;134(6):1310–7.

30. Khoudoun MV, Strati R, Armstrong L, Yanase N, Finkelman FD. Identification of markers that distinguish IgE from IgG-mediated anaphylaxis. Proc Natl Acad Sci USA. 2011;108(30):12413–8.

31. Liang KL, Yu SJ, Huang WC, Yen HR. Luteolin attenuates allergic nasal inflammation via inhibition of interleukin-4 in an allergic rhinitis mouse model and peripheral blood from human subjects with allergic rhinitis. Front Pharmacol. 2020;11:291.

32. Benson M, Reinholdt J, Cardell LO. Allergen-reactive antibodies are found in nasal fluids from patients with birch pollen-induced intermittent allergic rhinitis, but not in healthy controls. Allergy. 2003;58(5):386–92.

33. Smolodovskaya O, Freyzkhonava G, Voloshin S, Areifeva A, Chubarova A, Pavlushkina L, et al. Allergen-specific IgE and IgG4 patterns among patients with different allergic diseases. World Allergy Organ J. 2018;11(1):35.

34. Okamoto Y, Fujieda S, Okano M, Yoshida Y, Kakudo S, Masuyama K. House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis. Allergy. 2017;72(3):435–43.

35. Lai X, Li J, Xiao X, Liu E, Zhang C, Wang H, et al. Specific IgG4 production during house dust mite immunotherapy among age, gender and allergic disease populations. Int Arch Allergy Immunol. 2013;160(1):37–46.

36. van de Veen W, Akdis M. Role of IgG4 in IgE-mediated allergic responses. J Allergy Clin Immunol. 2016;138(5):1434–5.

37. Miranda DO, Silva DA, Fernandes JF, Queiros MG, Chiba HF, Ynoue LH, et al. Serum and salivary IgE, IgA, and IgG4 antibodies to Dermatophagoides pteronyssinus and its major allergens, Der p1 and Der p2, in allergic and nonallergic children. Clin Dev Immunol. 2011;2011:302739.

38. Hansen IS, Baeten DLF, den Dunnen J. The inflammatory function of human IgA. Cell Mol Life Sci. 2019;76(6):1041–55.

39. Davoodi A, Lotfi R, Mortazavi SH, Gorgin KA, Rezaiemanesh A, Salari F. Retinoid acid correlates with reduced serum IL-10 and TGF-beta in allergic rhinitis. Rep Biochem Mol Biol. 2021;9(4):399–407.

40. Keen C, Johansson S, Reinholdt J, Benson M, Wennergren G. Bet v 1-specific IgA increases during the pollen season but not after a single allergen challenge in children with birch pollen-induced intermittent allergic rhinitis. Pediatr Allergy Immunol. 2005;16(3):209–16.

41. Schwartz DP, Buckley RH. Serum IgE concentrations and skin reactivity to anti-IgE antibody in IgA-deficient patients. N Engl J Med. 1971;284(10):513–7.

42. Fageras M, Tomicic S, Voor T, Bjorksten B, Jenmalm MC. Slow salivary IgE and IgG4 production in allergic rhinitis. Pediatr Allergy Immunol. 2005;16(3):209–16.

43. Miranda DO, Silva DA, Fernandes JF, Queiros MG, Chiba HF, Ynoue LH, et al. Serum and salivary IgE, IgA, and IgG4 antibodies to Dermatophagoides pteronyssinus and its major allergens, Der p1 and Der p2, in allergic and nonallergic children. Clin Dev Immunol. 2011;2011:302739.

44. Hansen IS, Baeten DLF, den Dunnen J. The inflammatory function of human IgA. Cell Mol Life Sci. 2019;76(6):1041–55.

45. Davoodi A, Lotfi R, Mortazavi SH, Gorgin KA, Rezaiemanesh A, Salari F. Retinoid acid correlates with reduced serum IL-10 and TGF-beta in allergic rhinitis. Rep Biochem Mol Biol. 2021;9(4):399–407.

46. Keen C, Johansson S, Reinholdt J, Benson M, Wennergren G. Bet v 1-specific IgA increases during the pollen season but not after a single allergen challenge in children with birch pollen-induced intermittent allergic rhinitis. Pediatr Allergy Immunol. 2005;16(3):209–16.

47. Schwartz DP, Buckley RH. Serum IgE concentrations and skin reactivity to anti-IgE antibody in IgA-deficient patients. N Engl J Med. 1971;284(10):513–7.

48. Fageras M, Tomicic S, Voor T, Bjorksten B, Jenmalm MC. Slow salivary IgE and IgG4 production in allergic rhinitis. Pediatr Allergy Immunol. 2005;16(3):209–16.

49. Hansen IS, Baeten DLF, den Dunnen J. The inflammatory function of human IgA. Cell Mol Life Sci. 2019;76(6):1041–55.

50. Davoodi A, Lotfi R, Mortazavi SH, Gorgin KA, Rezaiemanesh A, Salari F. Retinoid acid correlates with reduced serum IL-10 and TGF-beta in allergic rhinitis. Rep Biochem Mol Biol. 2021;9(4):399–407.

51. Keen C, Johansson S, Reinholdt J, Benson M, Wennergren G. Bet v 1-specific IgA increases during the pollen season but not after a single allergen challenge in children with birch pollen-induced intermittent allergic rhinitis. Pediatr Allergy Immunol. 2005;16(3):209–16.

52. Aoi N, Masuda T, Murakami D, Yajima T, Mizubuchi H, Yamada H, et al. IL-15 prevents allergic rhinitis through reactivation of antigen-specific CD8+ cells. J Allergy Clin Immunol. 2006;117(6):1559–66.

53. van Cauwenberge P, Bachert C, Passalacqua G, Bousquet J, Canonica G, Durham SR, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy. 2000;55(2):116–34.

54. Konig K, Klemens C, Eder K, San NM, Becker S, Kramer MF, et al. Cytokine profiles in nasal fluid of patients with seasonal or persistent allergic rhinitis. Allergy Asthma Clin Immunol. 2015;11(1):26.

55. Nakano T, Kamei R, Fujimura T, Takaoka Y, Hori A, Lai CY, et al. Impact of histone H1 on the progression of allergic rhinitis and its suppression by neutralizing antibody in mice. PLoS ONE. 2016;11(4):e0153630.

56. Bozek A, Kolodziejczyk K, Bednarski P. The relationship between autoimmunity and specific immunotherapy for allergic diseases. Hum Vaccin Immunother. 2015;11(12):2764–8.

57. Yu X, Wang M, Cao Z. Reduced CD4+ T cell CCR3 expression in patients. Front Immunol. 2020;11:581180.

58. Sani MM, Ashari NSM, Abdullah B, Wong KK, Musa KI, Mohamud R, et al. Reduced CD4+ terminally differentiated effector memory T cells in moderate-severe house dust mite sensitized allergic rhinitis patients. Asian Pac J Allerg Immunol. 2019;37(3):138–46.

59. Zhang H, Cardell LO, Bjorkander J, Benson M, Wang H. Comprehensive profiling of peripheral immune cells and subsets in patients with intermittent allergic rhinitis compared to healthy controls and after treatment with glucocorticoids. Inflammation. 2013;36(4):821–9.

60. Mosmann TR, Coffmann RL. TH1 and TH2 cells: different patterns of proliferation of peripheral immune cells and subsets in patients with intermittent allergic rhinitis compared to healthy controls and after treatment with glucocorticoids. Inflammation. 2013;36(4):821–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more: biomedcentral.com/submissions